the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig
's disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn
Cautionary Statement Regarding Forward Looking Information Page: 1 2 3 4 Related medicine technology :1
. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering2
. FDA Approves NDA Supported By MedAvante Central Ratings3
. Cardinal Health Board Of Directors Approves Cash Dividend; Authorizes New $750 Million Share Repurchase Program4
. Neuralstem Updates ALS Stem Cell Trial Progress5
. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial6
. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder7
. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial8
. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.9
. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices10
. Neuralstem Announces Proposed Public Offering11
. Neuralstem to Raise $7.0 Million in Registered Direct Offering